Vaccine hesitancy about COVID-19 vaccines is a positive predictor of negative side effects with vaccination—an example of the "nocebo" effect—according to a study today in Scientific Reports.
Nocebo, a play on placebo, is a phenomenon in which people experience negative effects on health when they have negative views or expectations surrounding medical interventions.
The antibody reported as having been isolated at the IIBR is monoclonal, meaning it was derived from a single recovered cell and is thus potentially of more potent value in yielding a treatment.
The researchers found that Paxlovid reduced hospitalizations among people 65 and older by roughly 75% when given shortly after infection. That’s consistent with earlier results used to authorize the drug in the U.S. and other nations.
Waning vaccine-immunity and an increased incidence of COVID-19 during the Omicron outbreak led the Israeli Ministry of Health to recommend a fourth dose of BNT162b2 for high-risk individuals. This study assessed the effect of that dose for hospitalized patients with severe/critical, breakthrough COVID-19. ...
Among hospitalized patients with severe/critical breakthrough COVID-19, a recent fourth dose was associated with significant protection against mechanical ventilation or death, compared to three doses.
There is a real danger of another international COVID wave this summer, with the Delta variant possibly poised to make a comeback, new Israeli research suggests.
Rates of confirmed Omicron-related COVID infection and severe disease were lower after a fourth dose of the Pfizer-BioNTech vaccine, according to real-world data from Israel, although protection against confirmed infection seemed short-lived.
/cloudfront-us-east-2.images.arcpublishing.com/reuters/WYHSNV2FKJJA5FWI7U5UAD52UQ.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/EDM573BOABNTRE5SM44CTS7O2M.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/OJHNCLX3RRLCDE23A6GFBW3OFQ.jpg)
